Ann F Mohrbacher

Ann F Mohrbacher is an Associate Professor of Clinical Medicine, Medical Director of the Autologous Bone Marrow Transplant program, and Chair of the Biomedical Institutional Review Board 2. Her roles reflect her dedication to both clinical practice and academic research in hematology and oncology. She is actively involved in university-related committees, including the Post-Graduate Education Committee and the Clinical Investigations Committee, contributing to the advancement of medical education and research.

Dr. Mohrbacher's educational background includes an A.B. degree from Harvard University, earned Magna Cum Laude in 1983, and a medical degree from Harvard Medical School. These foundational achievements have shaped her expertise in clinical medicine and research.

Her research interests span hematology and oncology, with a focus on bone marrow transplantation, radioimmunotherapy for non-Hodgkin’s lymphoma, and B-cell targeted therapies. She explores the microenvironment of multiple myeloma, genetic variability in cytogenetic testing, and the emergence of EBV-related lymphomas. Her work often integrates clinical trials of novel agents like pembrolizumab and elotuzumab, emphasizing combination therapies and precision medicine approaches to improve patient outcomes.

Dr. Mohrbacher has been recognized for her contributions with the Career Development Award from the American Society of Clinical Oncology (1995). Her early academic excellence was highlighted by the A.B. Magna Cum Laude distinction and a Harvard University scholarship (both 1983).

In advising and grants, she has secured significant research funding for her studies but no specific students are listed. Her professional affiliations include membership in the Southern California Lymphoma Group and collaboration with the Microtransplantation Interest Group, which focus on innovative treatments for hematologic malignancies and transplant methodologies.

She collaborates closely with multidisciplinary teams through her roles in institutional review boards and clinical committees, ensuring ethical and effective research practices. Her work bridges preclinical studies and clinical applications, aiming to translate discoveries into improved therapeutic strategies.